{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:49:27Z","timestamp":1794638967325,"version":"4.9.1"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41582-018-0057-0","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T13:18:41Z","timestamp":1535116721000},"page":"606-617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Lafora disease \u2014 from pathogenesis to treatment strategies"],"prefix":"10.1038","volume":"14","author":[{"given":"Felix","family":"Nitschke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saija J.","family":"Ahonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmistha","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,24]]},"reference":[{"key":"57_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajmg.1575","volume":"106","author":"AV Delgado-Escueta","year":"2001","unstructured":"Delgado-Escueta, A. V., Ganesh, S. & Yamakawa, K. Advances in the genetics of progressive myoclonus epilepsy. Am. J. Med. Genet. 106, 129\u2013138 (2001).","journal-title":"Am. J. Med. Genet."},{"key":"57_CR2","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/B978-0-444-59565-2.00043-5","volume":"113","author":"JM Girard","year":"2013","unstructured":"Girard, J. M., Turnbull, J., Ramachandran, N. & Minassian, B. A. Progressive myoclonus epilepsy. Handb. Clin. Neurol. 113, 1731\u20131736 (2013).","journal-title":"Handb. Clin. Neurol."},{"key":"57_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02863929","volume":"6","author":"GR Lafora","year":"1911","unstructured":"Lafora, G. R. & Glueck, B. Beitrag zur Histopathologie der myoklonischen Epilepsie [German]. Z. Gesamte Neurol. Psychiatr. 6, 1\u201314 (1911).","journal-title":"Z. Gesamte Neurol. Psychiatr."},{"key":"57_CR4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.20.2.160","volume":"20","author":"M Sakai","year":"1970","unstructured":"Sakai, M., Austin, J., Witmer, F. & Trueb, L. Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20, 160\u2013176 (1970).","journal-title":"Neurology"},{"key":"57_CR5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","volume":"20","author":"BA Minassian","year":"1998","unstructured":"Minassian, B. A. et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 20, 171\u2013174 (1998).","journal-title":"Nat. Genet."},{"key":"57_CR6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/8.2.345","volume":"8","author":"JM Serratosa","year":"1999","unstructured":"Serratosa, J. M. et al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum. Mol. Genet. 8, 345\u2013352 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","volume":"35","author":"EM Chan","year":"2003","unstructured":"Chan, E. M. et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet. 35, 125\u2013127 (2003).","journal-title":"Nat. Genet."},{"key":"57_CR8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1474-4422(05)70043-0","volume":"4","author":"A Shahwan","year":"2005","unstructured":"Shahwan, A., Farrell, M. & Delanty, N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 4, 239\u2013248 (2005).","journal-title":"Lancet Neurol."},{"key":"57_CR9","first-page":"131","volume":"3","author":"D Madhavan","year":"2006","unstructured":"Madhavan, D. & Kuzniecky, R. I. Lafora disease. Rev. Neurol. Dis. 3, 131\u2013135 (2006).","journal-title":"Rev. Neurol. Dis."},{"key":"57_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1212\/WNL.55.3.341","volume":"55","author":"BA Minassian","year":"2000","unstructured":"Minassian, B. A. et al. Mutation spectrum and predicted function of laforin in Lafora\u2019s progressive myoclonus epilepsy. Neurology 55, 341\u2013346 (2000).","journal-title":"Neurology"},{"key":"57_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0887-8994(00)00276-9","volume":"25","author":"BA Minassian","year":"2001","unstructured":"Minassian, B. A. Lafora\u2019s disease: towards a clinical, pathologic, and molecular synthesis. Pediatr. Neurol. 25, 21\u201329 (2001).","journal-title":"Pediatr. Neurol."},{"key":"57_CR12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/humu.20954","volume":"30","author":"S Singh","year":"2009","unstructured":"Singh, S. & Ganesh, S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum. Mutat. 30, 715\u2013723 (2009).","journal-title":"Hum. Mutat."},{"key":"57_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/humu.9376","volume":"26","author":"L Ianzano","year":"2005","unstructured":"Ianzano, L. et al. Lafora progressive myoclonus epilepsy mutation database \u2014 EPM2A and NHLRC1 (EPM2B) genes. Hum. Mutat. 26, 397 (2005).","journal-title":"Hum. Mutat."},{"key":"57_CR14","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1093\/hmg\/ddg340","volume":"12","author":"ME Fern\u00e1ndez-S\u00e1nchez","year":"2003","unstructured":"Fern\u00e1ndez-S\u00e1nchez, M. E. et al. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum. Mol. Genet. 12, 3161\u20133171 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.molcel.2014.11.020","volume":"57","author":"M Raththagala","year":"2015","unstructured":"Raththagala, M. et al. Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease. Mol. Cell 57, 261\u2013272 (2015).","journal-title":"Mol. Cell"},{"key":"57_CR16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/brain\/awt353","volume":"137","author":"J Gayarre","year":"2014","unstructured":"Gayarre, J. et al. The phosphatase activity of laforin is dispensable to rescue Epm2a \u2212\/\u2212 mice from Lafora disease. Brain 137, 806\u2013818 (2014).","journal-title":"Brain"},{"key":"57_CR17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.15252\/emmm.201707608","volume":"9","author":"F Nitschke","year":"2017","unstructured":"Nitschke, F. et al. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease. EMBO Mol. Med. 9, 906\u2013917 (2017).","journal-title":"EMBO Mol. Med."},{"key":"57_CR18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/hmg\/11.11.1263","volume":"11","author":"S Ganesh","year":"2002","unstructured":"Ganesh, S. et al. Genotype\u2013phenotype correlations for EPM2A mutations in Lafora\u2019s progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum. Mol. Genet. 11, 1263\u20131271 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2148-11-225","volume":"11","author":"C Roma-Mateo","year":"2011","unstructured":"Roma-Mateo, C. et al. Lafora disease E3-ubiquitin ligase malin is related to TRIM32 at both the phylogenetic and functional level. BMC Evol. Biol. 11, 225 (2011).","journal-title":"BMC Evol. Biol."},{"key":"57_CR20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1212\/01.WNL.0000154519.10805.F7","volume":"64","author":"C G\u00f3mez-Abad","year":"2005","unstructured":"G\u00f3mez-Abad, C. et al. Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology 64, 982\u2013986 (2005).","journal-title":"Neurology"},{"key":"57_CR21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1528-1167.2006.00479.x","volume":"47","author":"S Franceschetti","year":"2006","unstructured":"Franceschetti, S. et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia 47, 640\u2013643 (2006).","journal-title":"Epilepsia"},{"key":"57_CR22","first-page":"399","volume":"97","author":"H Lohi","year":"2006","unstructured":"Lohi, H., Chan, E. M., Scherer, S. W. & Minassian, B. A. On the road to tractability: the current biochemical understanding of progressive myoclonus epilepsies. Adv. Neurol. 97, 399\u2013415 (2006).","journal-title":"Adv. Neurol."},{"key":"57_CR23","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.2005.039479","volume":"43","author":"S Singh","year":"2006","unstructured":"Singh, S. et al. Novel NHLRC1 mutations and genotype\u2013phenotype correlations in patients with Lafora\u2019s progressive myoclonic epilepsy. J. Med. Genet. 43, e48 (2006).","journal-title":"J. Med. Genet."},{"key":"57_CR24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1212\/01.WNL.0000133215.65836.03","volume":"63","author":"EM Chan","year":"2004","unstructured":"Chan, E. M. et al. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 63, 565\u2013567 (2004).","journal-title":"Neurology"},{"key":"57_CR25","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000258561.02248.2f","volume":"68","author":"H Lohi","year":"2007","unstructured":"Lohi, H. et al. Genetic diagnosis in Lafora disease: genotype\u2013phenotype correlations and diagnostic pitfalls. Neurology 68, 996\u20131001 (2007).","journal-title":"Neurology"},{"key":"57_CR26","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1093\/brain\/aws205","volume":"135","author":"J Turnbull","year":"2012","unstructured":"Turnbull, J. et al. Early-onset Lafora body disease. Brain 135, 2684\u20132698 (2012).","journal-title":"Brain"},{"key":"57_CR27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1528-1167.2007.01004.x","volume":"48","author":"C G\u00f3mez-Abad","year":"2007","unstructured":"G\u00f3mez-Abad, C. et al. Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation. Epilepsia 48, 1011\u20131014 (2007).","journal-title":"Epilepsia"},{"key":"57_CR28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.0013-9580.2004.33203.x","volume":"45","author":"G Annesi","year":"2004","unstructured":"Annesi, G. et al. A novel exon 1 mutation in a patient with atypical lafora progressive myoclonus epilepsy seen as childhood-onset cognitive deficit. Epilepsia 45, 294\u2013295 (2004).","journal-title":"Epilepsia"},{"key":"57_CR29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/j.1528-1167.2010.02692.x","volume":"51","author":"G Lesca","year":"2010","unstructured":"Lesca, G. et al. Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease. Epilepsia 51, 1691\u20131698 (2010).","journal-title":"Epilepsia"},{"key":"57_CR30","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/j.1528-1167.2005.00272.x","volume":"46","author":"B Baykan","year":"2005","unstructured":"Baykan, B. et al. Late-onset and slow-progressing Lafora disease in four siblings with EPM2B mutation. Epilepsia 46, 1695\u20131697 (2005).","journal-title":"Epilepsia"},{"key":"57_CR31","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/epi.12806","volume":"55","author":"E Ferlazzo","year":"2014","unstructured":"Ferlazzo, E. et al. Mild Lafora disease: clinical, neurophysiologic, and genetic findings. Epilepsia 55, e129\u2013e133 (2014).","journal-title":"Epilepsia"},{"key":"57_CR32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10048-009-0190-4","volume":"10","author":"M Traor\u00e9","year":"2009","unstructured":"Traor\u00e9, M. et al. Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease. Neurogenetics 10, 319\u2013323 (2009).","journal-title":"Neurogenetics"},{"key":"57_CR33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.pediatrneurol.2011.01.012","volume":"44","author":"FA Brackmann","year":"2011","unstructured":"Brackmann, F. A., Kiefer, A., Agaimy, A., Gencik, M. & Trollmann, R. Rapidly progressive phenotype of Lafora disease associated with a novel NHLRC1 mutation. Pediatr. Neurol. 44, 475\u2013477 (2011).","journal-title":"Pediatr. Neurol."},{"key":"57_CR34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jns.2012.12.006","volume":"325","author":"M Kecmanovic","year":"2013","unstructured":"Kecmanovic, M. et al. Lafora disease: severe phenotype associated with homozygous deletion of the NHLRC1 gene. J. Neurol. Sci. 325, 170\u2013173 (2013).","journal-title":"J. Neurol. Sci."},{"key":"57_CR35","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.eplepsyres.2014.08.017","volume":"108","author":"A Jara-Prado","year":"2014","unstructured":"Jara-Prado, A. et al. Late onset Lafora disease and novel EPM2A mutations: breaking paradigms. Epilepsy Res. 108, 1501\u20131510 (2014).","journal-title":"Epilepsy Res."},{"key":"57_CR36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/jhg.2012.29","volume":"57","author":"S Singh","year":"2012","unstructured":"Singh, S. & Ganesh, S. Phenotype variations in Lafora progressive myoclonus epilepsy: possible involvement of genetic modifiers? J. Hum. Genet. 57, 283\u2013285 (2012).","journal-title":"J. Hum. Genet."},{"key":"57_CR37","volume":"6","author":"R Guerrero","year":"2011","unstructured":"Guerrero, R. et al. A PTG variant contributes to a milder phenotype in Lafora disease. PLoS ONE 6, e21294 (2011).","journal-title":"PLoS ONE"},{"key":"57_CR38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002037","volume":"7","author":"J Turnbull","year":"2011","unstructured":"Turnbull, J. et al. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet. 7, e1002037 (2011).","journal-title":"PLoS Genet."},{"key":"57_CR39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"57_CR40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anndiagpath.2017.08.003","volume":"32","author":"G Nuovo","year":"2018","unstructured":"Nuovo, G. et al. Increased expression of importin-\u03b2, exportin-5 and nuclear transportable proteins in Alzheimer\u2019s disease aids anatomic pathologists in its diagnosis. Ann. Diagn. Pathol. 32, 10\u201316 (2018).","journal-title":"Ann. Diagn. Pathol."},{"key":"57_CR41","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","volume":"11","author":"S Ganesh","year":"2002","unstructured":"Ganesh, S. et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet. 11, 1251\u20131262 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR42","doi-asserted-by":"crossref","first-page":"25372","DOI":"10.1074\/jbc.M110.148668","volume":"285","author":"AA DePaoli-Roach","year":"2010","unstructured":"DePaoli-Roach, A. A. et al. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to Lafora Bodies and the accumulation of insoluble laforin. J. Biol. Chem. 285, 25372\u201325381 (2010).","journal-title":"J. Biol. Chem."},{"key":"57_CR43","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","volume":"23","author":"J Duran","year":"2014","unstructured":"Duran, J., Gruart, A., Garcia-Rocha, M., Delgado-Garcia, J. M. & Guinovart, J. J. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. Hum. Mol. Genet. 23, 3147\u20133156 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","volume":"75","author":"J Turnbull","year":"2014","unstructured":"Turnbull, J. et al. PTG protein depletion rescues malin-deficient Lafora disease in mouse. Ann. Neurol. 75, 442\u2013446 (2014).","journal-title":"Ann. Neurol."},{"key":"57_CR45","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/emmm.201200241","volume":"4","author":"J Duran","year":"2012","unstructured":"Duran, J. et al. Deleterious effects of neuronal accumulation of glycogen in flies and mice. EMBO Mol. Med. 4, 719\u2013729 (2012).","journal-title":"EMBO Mol. Med."},{"key":"57_CR46","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nature04723","volume":"441","author":"M Komatsu","year":"2006","unstructured":"Komatsu, M. et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880\u2013884 (2006).","journal-title":"Nature"},{"key":"57_CR47","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature04724","volume":"441","author":"T Hara","year":"2006","unstructured":"Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885\u2013889 (2006).","journal-title":"Nature"},{"key":"57_CR48","doi-asserted-by":"crossref","first-page":"15704","DOI":"10.1523\/JNEUROSCI.2392-12.2012","volume":"32","author":"J McMahon","year":"2012","unstructured":"McMahon, J. et al. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. J. Neurosci. 32, 15704\u201315714 (2012).","journal-title":"J. Neurosci."},{"key":"57_CR49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20141555","volume":"473","author":"DM Dias","year":"2016","unstructured":"Dias, D. M. et al. Biophysical characterization of laforin-carbohydrate interaction. Biochem. J. 473, 335\u2013345 (2016).","journal-title":"Biochem. J."},{"key":"57_CR50","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1111\/j.1742-4658.2009.07221.x","volume":"276","author":"C Christiansen","year":"2009","unstructured":"Christiansen, C. et al. The carbohydrate-binding module family 20 \u2014 diversity, structure, and function. FEBS J. 276, 5006\u20135029 (2009).","journal-title":"FEBS J."},{"key":"57_CR51","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/hmg\/ddh130","volume":"13","author":"EM Chan","year":"2004","unstructured":"Chan, E. M. et al. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Hum. Mol. Genet. 13, 1117\u20131129 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/abbi.1993.1342","volume":"304","author":"W Zhang","year":"1993","unstructured":"Zhang, W., DePaoli-Roach, A. A. & Roach, P. J. Mechanisms of multisite phosphorylation and inactivation of rabbit muscle glycogen synthase. Arch. Biochem. Biophys. 304, 219\u2013225 (1993).","journal-title":"Arch. Biochem. Biophys."},{"key":"57_CR53","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1093\/hmg\/ddi306","volume":"14","author":"H Lohi","year":"2005","unstructured":"Lohi, H. et al. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum. Mol. Genet. 14, 2727\u20132736 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0014-5793(80)81317-2","volume":"109","author":"JD Fontana","year":"1980","unstructured":"Fontana, J. D. The presence of phosphate in glycogen. FEBS Lett. 109, 85\u201392 (1980).","journal-title":"FEBS Lett."},{"key":"57_CR55","doi-asserted-by":"crossref","first-page":"30412","DOI":"10.1074\/jbc.M606117200","volume":"281","author":"CA Worby","year":"2006","unstructured":"Worby, C. A., Gentry, M. S. & Dixon, J. E. Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates. J. Biol. Chem. 281, 30412\u201330418 (2006).","journal-title":"J. Biol. Chem."},{"key":"57_CR56","doi-asserted-by":"crossref","first-page":"19262","DOI":"10.1073\/pnas.0707952104","volume":"104","author":"VS Tagliabracci","year":"2007","unstructured":"Tagliabracci, V. S. et al. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc. Natl Acad. Sci. USA 104, 19262\u201319266 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"57_CR57","doi-asserted-by":"crossref","first-page":"33816","DOI":"10.1074\/jbc.M807428200","volume":"283","author":"VS Tagliabracci","year":"2008","unstructured":"Tagliabracci, V. S. et al. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J. Biol. Chem. 283, 33816\u201333825 (2008).","journal-title":"J. Biol. Chem."},{"key":"57_CR58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.cmet.2013.04.006","volume":"17","author":"F Nitschke","year":"2013","unstructured":"Nitschke, F. et al. Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease. Cell Metab. 17, 756\u2013767 (2013).","journal-title":"Cell Metab."},{"key":"57_CR59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mam.2015.08.003","volume":"46","author":"PJ Roach","year":"2015","unstructured":"Roach, P. J. Glycogen phosphorylation and Lafora disease. Mol. Aspects Med. 46, 78\u201384 (2015).","journal-title":"Mol. Aspects Med."},{"key":"57_CR60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005907","volume":"4","author":"S Vernia","year":"2009","unstructured":"Vernia, S., Rubio, T., Heredia, M., Rodriguez de Cordoba, S. & Sanz, P. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. PLoS ONE 4, e5907 (2009).","journal-title":"PLoS ONE"},{"key":"57_CR61","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1093\/hmg\/ddq407","volume":"19","author":"SN Rao","year":"2010","unstructured":"Rao, S. N. et al. Sequestration of chaperones and proteasome into Lafora bodies and proteasomal dysfunction induced by Lafora disease-associated mutations of malin. Hum. Mol. Genet. 19, 4726\u20134734 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR62","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/hmg\/ddm006","volume":"16","author":"S Mittal","year":"2007","unstructured":"Mittal, S., Dubey, D., Yamakawa, K. & Ganesh, S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum. Mol. Genet. 16, 753\u2013762 (2007).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR63","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/hmg\/ddg253","volume":"12","author":"S Ganesh","year":"2003","unstructured":"Ganesh, S. et al. The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NIfU-like domain. Hum. Mol. Genet. 12, 2359\u20132368 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2006.08.008","volume":"10","author":"Y Wang","year":"2006","unstructured":"Wang, Y. et al. Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell 10, 179\u2013190 (2006).","journal-title":"Cancer Cell"},{"key":"57_CR65","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1074\/jbc.M708712200","volume":"283","author":"CA Worby","year":"2008","unstructured":"Worby, C. A., Gentry, M. S. & Dixon, J. E. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J. Biol. Chem. 283, 4069\u20134076 (2008).","journal-title":"J. Biol. Chem."},{"key":"57_CR66","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1742-4658.2012.08549.x","volume":"280","author":"MS Gentry","year":"2013","unstructured":"Gentry, M. S., Roma-Mateo, C. & Sanz, P. Laforin, a protein with many faces: glucan phosphatase, adapter proteinet et alii. FEBS J. 280, 525\u2013537 (2013).","journal-title":"FEBS J."},{"key":"57_CR67","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/hmg\/ddm339","volume":"17","author":"MC Solaz-Fuster","year":"2008","unstructured":"Solaz-Fuster, M. C. et al. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Hum. Mol. Genet. 17, 667\u2013678 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR68","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.biocel.2015.10.030","volume":"69","author":"P Sanchez-Martin","year":"2015","unstructured":"Sanchez-Martin, P., Roma-Mateo, C., Viana, R. & Sanz, P. Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex. Int. J. Biochem. Cell Biol. 69, 204\u2013214 (2015).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"57_CR69","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nn1998","volume":"10","author":"D Vilchez","year":"2007","unstructured":"Vilchez, D. et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat. Neurosci. 10, 1407\u20131413 (2007).","journal-title":"Nat. Neurosci."},{"key":"57_CR70","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1091\/mbc.e10-03-0227","volume":"21","author":"D Moreno","year":"2010","unstructured":"Moreno, D., Towler, M. C., Hardie, D. G., Knecht, E. & Sanz, P. The laforin\u2013malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase \u03b2 subunits. Mol. Biol. Cell 21, 2578\u20132588 (2010).","journal-title":"Mol. Biol. Cell"},{"key":"57_CR71","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.biocel.2013.04.019","volume":"45","author":"C Rubio-Villena","year":"2013","unstructured":"Rubio-Villena, C., Garcia-Gimeno, M. A. & Sanz, P. Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin\u2013malin complex. Int. J. Biochem. Cell Biol. 45, 1479\u20131488 (2013).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"57_CR72","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.biochem.78.101807.093809","volume":"78","author":"RJ Deshaies","year":"2009","unstructured":"Deshaies, R. J. & Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399\u2013434 (2009).","journal-title":"Annu. Rev. Biochem."},{"key":"57_CR73","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/hmg\/ddm320","volume":"17","author":"JM Tan","year":"2008","unstructured":"Tan, J. M. et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum. Mol. Genet. 17, 431\u2013439 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"57_CR74","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/emboj.2012.354","volume":"32","author":"JA Nathan","year":"2013","unstructured":"Nathan, J. A., Kim, H. T., Ting, L., Gygi, S. P. & Goldberg, A. L. Why do cell proteins linked to K63-polyubiquitin chains not associate with proteasomes? EMBO J. 32, 552\u2013565 (2013).","journal-title":"EMBO J."},{"key":"57_CR75","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1074\/jbc.M111.315135","volume":"287","author":"J Sharma","year":"2012","unstructured":"Sharma, J., Mulherkar, S., Mukherjee, D. & Jana, N. R. Malin regulates Wnt signaling pathway through degradation of dishevelled2. J. Biol. Chem. 287, 6830\u20136839 (2012).","journal-title":"J. Biol. Chem."},{"key":"57_CR76","doi-asserted-by":"crossref","first-page":"35034","DOI":"10.1074\/jbc.M005541200","volume":"275","author":"NM Fong","year":"2000","unstructured":"Fong, N. M. et al. Identification of binding sites on protein targeting to glycogen for enzymes of glycogen metabolism. J. Biol. Chem. 275, 35034\u201335039 (2000).","journal-title":"J. Biol. Chem."},{"key":"57_CR77","doi-asserted-by":"crossref","unstructured":"Zeeman, S. C., Kossmann, J. & Smith, A. M. in In Annual Review of Plant Biology Vol. 61 (eds Merchant, S. et al.) 209\u2013234 (2010).","DOI":"10.1146\/annurev-arplant-042809-112301"},{"key":"57_CR78","doi-asserted-by":"crossref","first-page":"8969","DOI":"10.1007\/s00216-013-7129-1","volume":"405","author":"RG Gilbert","year":"2013","unstructured":"Gilbert, R. G. et al. Improving human health through understanding the complex structure of glucose polymers. Anal. Bioanal. Chem. 405, 8969\u20138980 (2013).","journal-title":"Anal. Bioanal. Chem."},{"key":"57_CR79","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.carbpol.2013.09.061","volume":"101","author":"PO Powell","year":"2014","unstructured":"Powell, P. O. et al. Extraction, isolation and characterisation of phytoglycogen from su-1 maize leaves and grain. Carbohydr. Polym. 101, 423\u2013431 (2014).","journal-title":"Carbohydr. Polym."},{"key":"57_CR80","doi-asserted-by":"crossref","first-page":"22686","DOI":"10.1074\/jbc.M115.673897","volume":"290","author":"JM Irimia","year":"2015","unstructured":"Irimia, J. M. et al. Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice. J. Biol. Chem. 290, 22686\u201322698 (2015).","journal-title":"J. Biol. Chem."},{"key":"57_CR81","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1021\/bm1010189","volume":"11","author":"AC Wu","year":"2010","unstructured":"Wu, A. C. & Gilbert, R. G. Molecular weight distributions of starch branches reveal genetic constraints on biosynthesis. Biomacromolecules 11, 3539\u20133547 (2010).","journal-title":"Biomacromolecules"},{"key":"57_CR82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0144-8617(91)90071-J","volume":"16","author":"DJ Manners","year":"1991","unstructured":"Manners, D. J. Recent developments in our understanding of glycogen structure. Carbohydr. Polym. 16, 37\u201382 (1991).","journal-title":"Carbohydr. Polym."},{"key":"57_CR83","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0141-8130(98)00040-3","volume":"23","author":"A Buleon","year":"1998","unstructured":"Buleon, A., Colonna, P., Planchot, V. & Ball, S. Starch granules: structure and biosynthesis. Int. J. Biol. Macromol. 23, 85\u2013112 (1998).","journal-title":"Int. J. Biol. Macromol."},{"key":"57_CR84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0008-6215(00)81866-2","volume":"96","author":"K Umeki","year":"1981","unstructured":"Umeki, K. & Kainuma, K. Fine structure of Naegeli amylodextrin obtained by acid treatment of defatted waxy-maize starch \u2014 structural evidence to support the double-helix hypothesis. Carbohydr. Res. 96, 143\u2013159 (1981).","journal-title":"Carbohydr. Res."},{"key":"57_CR85","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1105\/tpc.113.109793","volume":"25","author":"S Bischof","year":"2013","unstructured":"Bischof, S. et al. Cecropia peltata accumulates starch or soluble glycogen by differentially regulating starch biosynthetic genes. Plant Cell 25, 1400\u20131415 (2013).","journal-title":"Plant Cell"},{"key":"57_CR86","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1093\/jxb\/ers235","volume":"63","author":"N Fujita","year":"2012","unstructured":"Fujita, N. et al. Elongated phytoglycogen chain length in transgenic rice endosperm expressing active starch synthase IIa affects the altered solubility and crystallinity of the storage \u03b1-glucan. J. Exp. Bot. 63, 5859\u20135872 (2012).","journal-title":"J. Exp. Bot."},{"key":"57_CR87","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081743","volume":"18","author":"M Sullivan","year":"2017","unstructured":"Sullivan, M., Nitschke, S., Steup, M., Minassian, B. & Nitschke, F. Pathogenesis of Lafora disease: transition of soluble glycogen to insoluble polyglucosan. Int. J. Mol. Sci. 18, E1743 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"57_CR88","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1042\/BJ20111416","volume":"441","author":"PJ Roach","year":"2012","unstructured":"Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D. & Tagliabracci, V. S. Glycogen and its metabolism: some new developments and old themes. Biochem. J. 441, 763\u2013787 (2012).","journal-title":"Biochem. J."},{"key":"57_CR89","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0008-6215(83)88142-7","volume":"115","author":"TN Palmer","year":"1983","unstructured":"Palmer, T. N., Macaskie, L. E. & Grewal, K. K. Spatial-distribution of unit chains in glycogen. Carbohydr. Res. 115, 139\u2013150 (1983).","journal-title":"Carbohydr. Res."},{"key":"57_CR90","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1103\/PhysRevLett.84.2754","volume":"84","author":"HR Petty","year":"2000","unstructured":"Petty, H. R., Worth, R. G. & Kindzelskii, A. L. Imaging sustained dissipative patterns in the metabolism of individual living cells. Phys. Rev. Lett. 84, 2754\u20132757 (2000).","journal-title":"Phys. Rev. Lett."},{"key":"57_CR91","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0968-0004(94)90019-1","volume":"19","author":"G Rickey Welch","year":"1994","unstructured":"Rickey Welch, G. & Easterby, J. S. Metabolic channeling versus free diffusion: transition-time analysis. Trends Biochem. Sci. 19, 193\u2013197 (1994).","journal-title":"Trends Biochem. Sci."},{"key":"57_CR92","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0074-7696(08)60528-8","volume":"192","author":"TY Aw","year":"1999","unstructured":"Aw, T. Y. Intracellular compartmentation of organelles and gradients of low molecular weight species. Int. Rev. Cytol. 192, 223\u2013253 (1999).","journal-title":"Int. Rev. Cytol."},{"key":"57_CR93","doi-asserted-by":"crossref","first-page":"25650","DOI":"10.1074\/jbc.M111.331611","volume":"287","author":"E Tiberia","year":"2012","unstructured":"Tiberia, E. et al. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease. J. Biol. Chem. 287, 25650\u201325659 (2012).","journal-title":"J. Biol. Chem."},{"key":"57_CR94","doi-asserted-by":"crossref","first-page":"34960","DOI":"10.1074\/jbc.M110.150839","volume":"285","author":"S Jiang","year":"2010","unstructured":"Jiang, S. et al. Starch binding domain-containing protein 1\/genethonin 1 is a novel participant in glycogen metabolism. J. Biol. Chem. 285, 34960\u201334971 (2010).","journal-title":"J. Biol. Chem."},{"key":"57_CR95","first-page":"28","volume":"7","author":"P Wang","year":"2016","unstructured":"Wang, P. et al. SGK1 (glucose transport), dishevelled2 (wnt signaling), LC3\/p62 (autophagy) and p53 (apoptosis) proteins are unaltered in Lafora disease. All Results J. Biol. 7, 28\u201333 (2016).","journal-title":"All ResultsJ. Biol."},{"key":"57_CR96","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jns.2011.02.011","volume":"304","author":"HM Khiari","year":"2011","unstructured":"Khiari, H. M., Lesca, G., Malafosse, A. & Mrabet, A. A novel exon 3 mutation in a Tunisian patient with Lafora\u2019s disease. J. Neurol. Sci. 304, 136\u2013137 (2011).","journal-title":"J. Neurol. Sci."},{"key":"57_CR97","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1528-1167.2006.00526.x","volume":"47","author":"V Villanueva","year":"2006","unstructured":"Villanueva, V., Alvarez-Linera, J., Gomez-Garre, P., Gutierrez, J. & Serratosa, J. M. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease. Epilepsia 47, 788\u2013792 (2006).","journal-title":"Epilepsia"},{"key":"57_CR98","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1212\/01.WNL.0000096017.19978.CB","volume":"61","author":"DM Andrade","year":"2003","unstructured":"Andrade, D. M. et al. Skin biopsy in Lafora disease: genotype\u2013phenotype correlations and diagnostic pitfalls. Neurology 61, 1611\u20131614 (2003).","journal-title":"Neurology"},{"key":"57_CR99","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eplepsyres.2006.01.007","volume":"69","author":"S Cardinali","year":"2006","unstructured":"Cardinali, S. et al. A pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy Res. 69, 129\u2013134 (2006).","journal-title":"Epilepsy Res."},{"key":"57_CR100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ebcr.2013.07.003","volume":"1","author":"K Schorlemmer","year":"2013","unstructured":"Schorlemmer, K. et al. Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease). Epilepsy Behav. Case Rep. 1, 118\u2013121 (2013).","journal-title":"Epilepsy Behav. Case Rep."},{"key":"57_CR101","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebcr.2014.09.003","volume":"2","author":"M Dirani","year":"2014","unstructured":"Dirani, M., Nasreddine, W., Abdulla, F. & Beydoun, A. Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav. Case Rep. 2, 164\u2013166 (2014).","journal-title":"Epilepsy Behav. Case Rep."},{"key":"57_CR102","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yebeh.2016.06.041","volume":"62","author":"D Goldsmith","year":"2016","unstructured":"Goldsmith, D. & Minassian, B. A. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 62, 132\u2013135 (2016).","journal-title":"Epilepsy Behav."},{"key":"57_CR103","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebcr.2013.08.002","volume":"1","author":"S Hajnsek","year":"2013","unstructured":"Hajnsek, S. et al. Vagus nerve stimulation in Lafora body disease. Epilepsy Behav. Case Rep. 1, 150\u2013152 (2013).","journal-title":"Epilepsy Behav. Case Rep."},{"key":"57_CR104","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1684\/epd.2017.0892","volume":"19","author":"MA Mikati","year":"2017","unstructured":"Mikati, M. A. & Tabbara, F. Managing Lafora body disease with vagal nerve stimulation. Epilept. Disord. 19, 82\u201386 (2017).","journal-title":"Epilept. Disord."},{"key":"57_CR105","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167\u20131174 (2001).","journal-title":"J. Clin. Invest."},{"key":"57_CR106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1471-4159.2009.05916.x","volume":"109","author":"GV Ronnett","year":"2009","unstructured":"Ronnett, G. V., Ramamurthy, S., Kleman, A. M., Landree, L. E. & Aja, S. AMPK in the brain: its roles in energy balance and neuroprotection. J. Neurochem. 109, 17\u201323 (2009).","journal-title":"J. Neurochem."},{"key":"57_CR107","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrm2249","volume":"8","author":"DG Hardie","year":"2007","unstructured":"Hardie, D. G. AMP-activated\/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell. Biol. 8, 774\u2013785 (2007).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"57_CR108","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbrc.2017.01.157","volume":"484","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. Chronic metformin treatment facilitates seizure termination. Biochem. Biophys. Res. Commun. 484, 450\u2013455 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"57_CR109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2013.11.002","volume":"63","author":"M Dulovic","year":"2014","unstructured":"Dulovic, M. et al. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol. Dis 63, 1\u201311 (2014).","journal-title":"Neurobiol. Dis"},{"key":"57_CR110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11011-013-9475-2","volume":"29","author":"G Ashabi","year":"2014","unstructured":"Ashabi, G., Khodagholi, F., Khalaj, L., Goudarzvand, M. & Nasiri, M. Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK\/PGC-1\u03b1 pathway. Metab. Brain Dis. 29, 47\u201358 (2014).","journal-title":"Metab. Brain Dis."},{"key":"57_CR111","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1007\/s12035-015-9091-8","volume":"53","author":"A Berthier","year":"2016","unstructured":"Berthier, A. et al. Pharmacological interventions to ameliorate neuropathological symptoms in a mouse model of Lafora disease. Mol. Neurobiol. 53, 1296\u20131309 (2016).","journal-title":"Mol. Neurobiol."},{"key":"57_CR112","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/WNR.0000000000000751","volume":"28","author":"G Sanchez-Elexpuru","year":"2017","unstructured":"Sanchez-Elexpuru, G., Serratosa, J. M., Sanz, P. & Sanchez, M. P. 4-PBA and metformin decrease sensitivity to PTZ-induced seizures in a malin knockout model of Lafora disease. Neuroreport 28, 268\u2013271 (2017).","journal-title":"Neuroreport"},{"key":"57_CR113","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/epi.13656","volume":"58","author":"G Sanchez-Elexpuru","year":"2017","unstructured":"Sanchez-Elexpuru, G., Serratosa, J. M. & Sanchez, M. P. Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease. Epilepsia 58, 467\u2013475 (2017).","journal-title":"Epilepsia"},{"key":"57_CR114","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/nar\/13.17.6265","volume":"13","author":"JF Burke","year":"1985","unstructured":"Burke, J. F. & Mogg, A. E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13, 6265\u20136272 (1985).","journal-title":"Nucleic Acids Res."},{"key":"57_CR115","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01093-9","volume":"7","author":"F Bolze","year":"2017","unstructured":"Bolze, F., Mocek, S., Zimmermann, A. & Klingenspor, M. Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes. Sci. Rep. 7, 1020 (2017).","journal-title":"Sci. Rep."},{"key":"57_CR116","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","volume":"163","author":"JP Clancy","year":"2001","unstructured":"Clancy, J. P. et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 163, 1683\u20131692 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"57_CR117","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","volume":"349","author":"M Wilschanski","year":"2003","unstructured":"Wilschanski, M. et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349, 1433\u20131441 (2003).","journal-title":"N. Engl. J. Med."},{"key":"57_CR118","first-page":"15","volume":"22","author":"L Politano","year":"2003","unstructured":"Politano, L. et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22, 15\u201321 (2003).","journal-title":"Acta Myol."},{"key":"57_CR119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1212\/01.wnl.0000194212.31318.fc","volume":"66","author":"A Schroers","year":"2006","unstructured":"Schroers, A. et al. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology 66, 285\u2013286 (2006).","journal-title":"Neurology"},{"key":"57_CR120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","volume":"27","author":"KA Wargo","year":"2014","unstructured":"Wargo, K. A. & Edwards, J. D. Aminoglycoside-induced nephrotoxicity. J. Pharm. Pract. 27, 573\u2013577 (2014).","journal-title":"J. Pharm. Pract."},{"key":"57_CR121","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tox.2008.04.015","volume":"249","author":"OW Guthrie","year":"2008","unstructured":"Guthrie, O. W. Aminoglycoside induced ototoxicity. Toxicology 249, 91\u201396 (2008).","journal-title":"Toxicology"},{"key":"57_CR122","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","volume":"241","author":"J Saraiva","year":"2016","unstructured":"Saraiva, J., Nobre, R. J. & de Almeida, L. P. Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9. J. Control. Release 241, 94\u2013109 (2016).","journal-title":"J. Control. Release"},{"key":"57_CR123","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","volume":"120","author":"SR Choudhury","year":"2017","unstructured":"Choudhury, S. R. et al. Viral vectors for therapy of neurologic diseases. Neuropharmacology 120, 63\u201380 (2017).","journal-title":"Neuropharmacology"},{"key":"57_CR124","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fnagi.2017.00317","volume":"9","author":"AT Jan","year":"2017","unstructured":"Jan, A. T. et al. Perspective insights of exosomes in neurodegenerative diseases: a critical appraisal. Front. Aging Neurosci. 9, 317 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"57_CR125","doi-asserted-by":"crossref","unstructured":"Duskey, J. T. et al. in International Review of Neurobiology 1\u201328 (Elsevier, 2017).","DOI":"10.1016\/bs.irn.2017.08.006"},{"key":"57_CR126","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172\u20131179 (2017).","journal-title":"Nat. Neurosci."},{"key":"57_CR127","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat.\u00a0Biotechnol. 27, 59\u201365 (2009).","journal-title":"Nat. Biotechnol."},{"key":"57_CR128","first-page":"615","volume":"7","author":"MM Bottros","year":"2014","unstructured":"Bottros, M. M. & Christo, P. J. Current perspectives on intrathecal drug delivery. J. Pain Res. 7, 615\u2013626 (2014).","journal-title":"J. Pain Res."},{"key":"57_CR129","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hach\u00e9","year":"2016","unstructured":"Hach\u00e9, M. et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J. Child Neurol. 31, 899\u2013906 (2016).","journal-title":"J. Child Neurol."},{"key":"57_CR130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","volume":"20","author":"SJ Gray","year":"2013","unstructured":"Gray, S. J., Kalburgi, S. N., McCown, T. J. & Samulski, R. J. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20, 450\u2013459 (2013).","journal-title":"Gene Ther."},{"key":"57_CR131","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","volume":"23","author":"L Samaranch","year":"2011","unstructured":"Samaranch, L. et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23, 382\u2013389 (2011).","journal-title":"Hum. Gene Ther."},{"key":"57_CR132","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","volume":"19","author":"SJ Gray","year":"2011","unstructured":"Gray, S. J. et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol.\u00a0Ther. 19, 1058\u20131069 (2011).","journal-title":"Mol. Ther."},{"key":"57_CR133","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","volume":"11","author":"N Bessis","year":"2004","unstructured":"Bessis, N., GarciaCozar, F. J. & Boissier, M. C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 11 (Suppl. 1), S10\u2013S17 (2004).","journal-title":"Gene Ther."},{"key":"57_CR134","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158 (2013).","journal-title":"Science"},{"key":"57_CR135","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1750-3639.2010.00394.x","volume":"20","author":"N Cartier","year":"2010","unstructured":"Cartier, N. & Aubourg, P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol. 20, 857\u2013862 (2010).","journal-title":"Brain Pathol."},{"key":"57_CR136","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1021\/acs.molpharmaceut.5b00233","volume":"12","author":"A Auger","year":"2015","unstructured":"Auger, A. et al. Efficient delivery of structurally diverse protein cargo into mammalian cells by a bacterial toxin. Mol. Pharm. 12, 2962\u20132971 (2015).","journal-title":"Mol. Pharm."},{"key":"57_CR137","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","volume":"74","author":"BA Pederson","year":"2013","unstructured":"Pederson, B. A. et al. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann. Neurol. 74, 297\u2013300 (2013).","journal-title":"Ann. Neurol."},{"key":"57_CR138","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mam.2015.08.007","volume":"46","author":"J Duran","year":"2015","unstructured":"Duran, J. & Guinovart, J. J. Brain glycogen in health and disease. Mol. Aspects Med. 46, 70\u201377 (2015).","journal-title":"Mol. Aspects Med."},{"key":"57_CR139","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ymgme.2009.07.012","volume":"98","author":"JM Cameron","year":"2009","unstructured":"Cameron, J. M. et al. Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts. Mol. Genet. Metab. 98, 378\u2013382 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"57_CR140","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa066691","volume":"357","author":"G Kollberg","year":"2007","unstructured":"Kollberg, G. et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N. Engl. J. Med. 357, 1507\u20131514 (2007).","journal-title":"N. Engl. J. Med."},{"key":"57_CR141","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.nmd.2011.08.008","volume":"22","author":"S Sukigara","year":"2012","unstructured":"Sukigara, S. et al. Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgia. Neuromuscul. Disord. 22, 162\u2013165 (2012).","journal-title":"Neuromuscul. Disord."},{"key":"57_CR142","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1128\/MCB.24.16.7179-7187.2004","volume":"24","author":"BA Pederson","year":"2004","unstructured":"Pederson, B. A. et al. Abnormal cardiac development in the absence of heart glycogen. Mol. Cell. Biol. 24, 7179\u20137187 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"57_CR143","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/bies.950050312","volume":"5","author":"WJ Whelan","year":"1986","unstructured":"Whelan, W. J. The initiation of glycogen synthesis. Bioessays 5, 136\u2013140 (1986).","journal-title":"Bioessays"},{"key":"57_CR144","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cmet.2017.06.008","volume":"26","author":"G Testoni","year":"2017","unstructured":"Testoni, G. et al. Lack of glycogenin causes glycogen accumulation and muscle function impairment. Cell\u00a0Metab. 26, 256\u2013266. e4 (2017).","journal-title":"Cell Metab."},{"key":"57_CR145","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ana.24284","volume":"76","author":"E Malfatti","year":"2014","unstructured":"Malfatti, E. et al. A new muscle glycogen storage disease associated with glycogenin-1 deficiency. Ann.\u00a0Neurol. 76, 891\u2013898 (2014).","journal-title":"Ann. Neurol."},{"key":"57_CR146","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ane.12865","volume":"137","author":"C Hedberg-Oldfors","year":"2018","unstructured":"Hedberg-Oldfors, C. et al. Polyglucosan myopathy and functional characterization of a novel GYG1 mutation. Acta Neurol. Scand. 137, 308\u2013315 (2018).","journal-title":"Acta Neurol. Scand."},{"key":"57_CR147","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.pa.36.040196.000543","volume":"36","author":"ST Crooke","year":"1996","unstructured":"Crooke, S. T. & Bennett, C. F. Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 107\u2013129 (1996).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"57_CR148","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett, C. F. & Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259\u2013293 (2010).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"57_CR149","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch, K. M. & Miller, T. M. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 94, 1056\u20131070 (2017).","journal-title":"Neuron"},{"key":"57_CR150","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith, R. A. et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290\u20132296 (2006).","journal-title":"J. Clin. Invest."},{"key":"57_CR151","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","volume":"33","author":"SL DeVos","year":"2013","unstructured":"DeVos, S. L. et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33, 12887\u201312897 (2013).","journal-title":"J. Neurosci."},{"key":"57_CR152","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74, 1031\u20131044 (2012).","journal-title":"Neuron"},{"key":"57_CR153","doi-asserted-by":"crossref","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","volume":"110","author":"C Lagier-Tourenne","year":"2013","unstructured":"Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 110, E4530\u2013E4539 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"57_CR154","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18 (2011).","journal-title":"Sci. Transl. Med."},{"key":"57_CR155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary, R. S., Norris, D., Yu, R. & Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46\u201351 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"57_CR156","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634\u20131644 (2010).","journal-title":"Genes Dev."},{"key":"57_CR157","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","volume":"82","author":"Y Hua","year":"2008","unstructured":"Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F. & Krainer, A. R. Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82, 834\u2013848 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"57_CR158","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein, C. A. & Castanotto, D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther. 25, 1069\u20131075 (2017).","journal-title":"Mol. Ther."},{"key":"57_CR159","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrg2968","volume":"12","author":"BL Davidson","year":"2011","unstructured":"Davidson, B. L. & McCray, P. B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329\u2013340 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"57_CR160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1126\/science.1121638","volume":"311","author":"IJ MacRae","year":"2006","unstructured":"MacRae, I. J. et al. Structural basis for double-stranded RNA processing by Dicer. Science 311, 195\u2013198 (2006).","journal-title":"Science"},{"key":"57_CR161","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol. Ther. 19, 2152\u20132162 (2011).","journal-title":"Mol. Ther."},{"key":"57_CR162","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820\u20135825 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"57_CR163","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","volume":"343","author":"Y Machida","year":"2006","unstructured":"Machida, Y. et al. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Commun. 343, 190\u2013197 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"57_CR164","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"57_CR165","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nmeth.2649","volume":"10","author":"P Mali","year":"2013","unstructured":"Mali, P., Esvelt, K. M. & Church, G. M. Cas9 as a versatile tool for engineering biology. Nat. Methods 10, 957\u2013963 (2013).","journal-title":"Nat. Methods"},{"key":"57_CR166","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR\u2013Cas9. Science 346, 1258096 (2014).","journal-title":"Science"},{"key":"57_CR167","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","volume":"47","author":"JR Chapman","year":"2012","unstructured":"Chapman, J. R., Taylor, M. R. & Boulton, S. J. Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell 47, 497\u2013510 (2012).","journal-title":"Mol. Cell"},{"key":"57_CR168","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1128\/MCB.23.16.5706-5715.2003","volume":"23","author":"K Rothkamm","year":"2003","unstructured":"Rothkamm, K., Kr\u00fcger, I., Thompson, L. H. & L\u00f6brich, M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol. Cell. Biol. 23, 5706\u20135715 (2003).","journal-title":"Mol. Cell. Biol."},{"key":"57_CR169","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nbt.3055","volume":"33","author":"L Swiech","year":"2015","unstructured":"Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR\u2013Cas9. Nat. Biotechnol. 33, 102\u2013106 (2015).","journal-title":"Nat. Biotechnol."},{"key":"57_CR170","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt, R. J. et al. CRISPR\u2013Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440\u2013455 (2014).","journal-title":"Cell"},{"key":"57_CR171","doi-asserted-by":"crossref","DOI":"10.1038\/srep20611","volume":"6","author":"Y Shinmyo","year":"2016","unstructured":"Shinmyo, Y. et al. CRISPR\/Cas9-mediated gene knockout in the mouse brain using in utero electroporation. Sci. Rep 6, 20611 (2016).","journal-title":"Sci. Rep"},{"key":"57_CR172","volume":"8","author":"W Feng","year":"2017","unstructured":"Feng, W. et al. Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. Nat. Commun. 8, 14758 (2017).","journal-title":"Nat. Commun."},{"key":"57_CR173","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"57_CR174","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1042\/BCJ20170469","volume":"474","author":"LJ Solmesky","year":"2017","unstructured":"Solmesky, L. J. et al. A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease. Biochem. J. 474, 3403\u20133420 (2017).","journal-title":"Biochem. J."},{"key":"57_CR175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jnc.12277","volume":"127","author":"O Kakhlon","year":"2013","unstructured":"Kakhlon, O. et al. Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase. J. Neurochem. 127, 101\u2013113 (2013).","journal-title":"J. Neurochem."},{"key":"57_CR176","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ymgme.2010.05.001","volume":"100","author":"KM Ashe","year":"2010","unstructured":"Ashe, K. M. et al. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. Mol. Genet. Metab. 100, 309\u2013315 (2010).","journal-title":"Mol. Genet. Metab."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-018-0057-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-018-0057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-018-0057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:44:52Z","timestamp":1720539892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-018-0057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,24]]},"references-count":176,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1038\/s41582-018-0057-0","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,24]]},"assertion":[{"value":"24 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}